Galcanezumab may effectively Alleviate Menstrual Migraine: Post-hoc Analysis
Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated significant effectiveness in patients with episodic migraine experiencing menstrual migraine compared with placebo. The study findings were presented at the 63rd Annual Scientific Meeting of the American Headache Society.
A high proportion (>50%) of women report an association between migraine and menstruation. In women with menstrually related migraine (MRM), perimenstrual attacks are longer, more disabling, and treatment-resistant compared with non-menstrually related attacks. Therefore, Dr MacGregor E and his team conducted a study to evaluate the efficacy of galcanezumab, a calcitonin gene-related peptide antibody, in reducing migraine headache days in women with menstrual migraine (MM), defined as MRM or pure menstrual migraine (PMM).
In this post-hoc analysis, the researchers evaluated three-phase 3 randomized, double-blind, placebo-controlled studies of galcanezumab, EVOLVE-1, EVOLVE-2 and CONQUER. They identified 459 women from three studies who have completed daily electronic diaries with headache information and menstrual status and were randomly assigned to receive either 120 mg galcanezumab (EVOLVE-1, EVOLVE-2: n = 144; CONQUER: n = 47) per month or placebo (EVOLVE-1, EVOLVE-2: n = 315; CONQUER: n = 52). The major outcome assessed was overall mean change from baseline in monthly migraine headache days, monthly migraine headache days with acute headache medication use, 50% response rate and Migraine-Specific Quality of Life Questionnaire Role Function-Restrictive (MSQ-RFR) domain. The researchers used linear mixed model repeated measures to assess outcomes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.